View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
May 24, 2011

Inspra Found to Reduce New Onset Atrial Fibrillation

Pfizer has announced positive results from the EMPHASIS-HF trial2, which revealed that Inspra (eplerenone) reduces the incidence of new onset atrial fibrillation or flutter in patients with systolic heart failure and mild symptoms. The Phase IIIB, multinational, randomised, double-blind

By cms admin

Pfizer has announced positive results from the EMPHASIS-HF trial2, which revealed that Inspra (eplerenone) reduces the incidence of new onset atrial fibrillation or flutter in patients with systolic heart failure and mild symptoms.

The Phase IIIB, multinational, randomised, double-blind, placebo-controlled and parallel-group trial enrolled 2,737 patients with chronic systolic heart failure and mild symptoms.

New onset atrial fibrillation or flutter occurred in 25 patients in the Inspra group, compared to 40 patients in the placebo group.

The study also reported that Inspra reduces the risk of cardiovascular mortality and morbidity in stable patients with left ventricular dysfunction.

Adverse reactions seen in patients who were given the drug include hyperkalemia, increased creatinine and hypertension.

In Japan, Inspra is approved for the treatment of hypertension.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology